CANBERRA: Australia has asked the European Commission to review a decision by Italy to block a shipment of AstraZeneca's COVID-19 vaccine, while stressing on Friday (Mar 5) the missing doses would not affect the rollout of Australia's inoculation programme.
Italy, supported by the European Commission, barred the planned export of about 250,000 doses of AstraZeneca's vaccine after the drug manufacturer failed to meet its European Union contract commitments.
"Australia has raised the issue with the European Commission through multiple channels, and in particular we have asked the European Commission to review this decision,” Australian Health Minister Greg Hunt told reporters in Melbourne.
Hunt said Australia had already received 300,000 doses of AstraZeneca's COVID-19 vaccine, which would last until local production of the vaccine ramps up.
Australia began its inoculation programme two weeks ago, vaccinating frontline health staff and senior citizens with Pfizer's COVID-19 vaccine though doses of that vaccine are limited amid tight global supplies.
AstraZeneca did not immediately reply to a request for comment.
"The world is in quite uncharted territory at present, and it is unsurprising that some countries will tear up the rule book when they are in uncharted territory," Australian Finance Minister Simon Birmingham told Sky News.
"This is a demonstration of really how well Australia continues to do compared to the desperation of other countries."
Italy's move came just days after Prime Minister Mario Draghi, who took office last month, told fellow EU leaders that the bloc needed to speed up vaccinations and crackdown on pharma companies that failed to deliver on promised supplies.
EU countries started inoculations at the end of December, but are moving at a far slower pace than many other nations, with officials blaming the slow progress in part on supply problems with key manufacturers.
Australian officials on Friday administered the first dose of the AstraZeneca vaccine, to a doctor.
Australia has ordered 53.8 million doses of the AstraZeneca vaccine, which was developed in conjunction with the University of Oxford. Local pharmaceutical company CSL has secured the rights to manufacture 50 million of those doses in Australia and expects to release the first batch near the end of March.
The locally produced doses will provide the backbone of Australia's inoculation programme, which officials hope to complete by October.
Australia is under less pressure than many other countries, having recorded just less than 29,000 COVID-19 cases and 909 deaths. The lower infection and death tallies have been helped by strict lockdowns, speedy tracking systems and border closures.